KEYTRUDA is the first and only immunotherapy-based regimen to show a statistically significant and clinically meaningful improvement in overall survival
TROPION-Lung01, evaluating AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan versus chemotherapy, previously met the dual primary endpoint of progression-free survival in the overall trial population
Globally, colorectal cancer impacts 1.9 million people each year, standing as a leading cause of cancer mortality
PICCOLO trial met its primary endpoint of objective response rate (ORR)
Combination shows consistent benefit across prespecified post-progression outcomes
Keynote -564 is the first Phase 3 trial to demonstrate superior overall survival (OS) with adjuvant therapy compared to placebo in patients with RCC
Collaboration streamlines patient access to oncology clinical trials
Lays foundation stone of NIPER Hyderabad and NIPER Raebareli
First-ever brain chemistry database will allow clinicians to quickly infer brain biomarker data to support the diagnostic process in conditions such as Alzheimer's Disease
In 2022, darolutamide was FDA-approved in combination with docetaxel chemotherapy for adults with metastatic hormone-sensitive prostate cancer
Subscribe To Our Newsletter & Stay Updated
